Načítá se...
AT-07 A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL
BACKGROUND: Ependymoma is an uncommon primary CNS tumor in adults, with no standardized treatment at recurrence. Little is known of the symptom burden associated with potential treatments. CERN-0802 combined lapatinib (targets ErbB1, ErbB2) with dose-dense temozolomide for patients with recurrent di...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4217844/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|